Cellevolve Announces Expansive Global Collaboration with Seattle Children’s Therapeutics to Advance Research for Childhood Brain Cancers

 The Company Also Announced Immunotherapy Pioneer Dr. Michael Jensen as Founding Advisor 

• Broad research collaboration focuses on BrainChild program, a suite of five multiplex chimeric antigen receptors (CARs) that initially targets pediatric central nervous system (CNS) malignancies with limited therapeutic options.
• Cellevolve will also leverage Seattle Children’s renowned Cure Factory® facility for early clinical Good Manufacturing Practice (GMP) research on novel CARs and its new VectorWorks facility to expand lentiviral vector manufacturing capacity.
• Dr. Michael Jensen, leading pediatric cancer research scientist and Chief Therapeutics Officer at Seattle Children’s Therapeutics, will join Cellevolve as Founding Advisor and Chair of the Scientific Advisory Board.

Excerpt from the Press Release:

SAN FRANCISCO & SEATTLE–(BUSINESS WIRE)–Cellevolve Bio (“the Company” or “Cellevolve”), a development and commercialization company focused on cell therapies and Seattle Children’s Therapeutics, a venture at Seattle Children’s, bringing cutting edge, curative technologies and therapies to defeat pediatric cancer and other diseases that impact children, today announced a collaboration aimed at developing and commercializing a suite of novel multiplex CARs for the treatment of pediatric CNS malignancies. The collaboration utilizes Seattle Children’s renowned Cure Factory® facility for early clinical GMP research on novel CARs, and its new VectorWorks facility to expand lentiviral vector manufacturing for tailored cell therapy products. Additionally, Dr. Michael Jensen, acclaimed pediatric cancer research scientist, co-founder of leading cell therapy companies, Juno and Umoja, and Chief Therapeutics Officer at Seattle Children’s Therapeutics, will be named Cellevolve’s Founding Advisor and Chair, Scientific Advisory Board.

Cellevolve and Seattle Children’s Therapeutics will collaborate on advancing the BrainChild research program, which currently includes three pediatric Phase 1 clinical trials at Seattle Children’s – BrainChild-01, BrainChild-02 and BrainChild-03. Both organizations have agreed to an exclusive agreement in which Seattle Children’s Therapeutics will conduct early-stage discovery and pre-clinical, Phase 1 development while Cellevolve leads Phase 2 and subsequent clinical development with key Seattle Children’s Therapeutics involvement.

“Today is an exciting day for Cellevolve as we continue to grow our pipeline through this monumental collaboration with Seattle Children’s Therapeutics, a world class pediatric research organization with a demonstrated ability to translate promising research into novel therapies,” said Derrell Porter, MD, MBA, Founder and Chief Executive Officer, Cellevolve. “Cellevolve is thrilled to be able to work more closely with one of the brightest minds in cell therapy in Dr. Michael Jensen, an internationally recognized, pediatric hematologist-oncologist who has an unparalleled devotion to developing and testing promising T-cell treatments.^”

Click the button below to read the entire Press Release:

Continue Reading The Press Release